Oncology

A rare case of soft-tissue sarcoma spreading to the heart shows how multimodal imaging guided diagnosis and care in a 36-year-old man.

Sustainable models require asking what a result shows, what design produced it, and whether the design was built to measure value or just produce a number.

As AI proliferates, patients, caregivers, and others outside the medical world are using its tools to deal with cancer, but not always in obvious ways.

The 2026 COA Payer Exchange and Innovation Summit began with a panel on AI and the ever-changing digital infrastructure in community oncology.

Caregiver shortages limit access to transplant, CAR T, and bispecific therapies, and no system offers replacement support, says Duke's Thomas LeBlanc, MD, MA.

Experts tackled CAR T access, trial equity, and overtreatment in breast cancer at an AJMC Institute for Value-Based Medicine event in San Francisco.

The Community Oncology Alliance is the only national organization focused exclusively on community oncology; it advocates for independent practices where most Americans with cancer receive treatment.

Tennessee Oncology appoints Kate Baker as medical director of supportive cancer care services, to expand services boosting symptom relief, survivorship resources, and whole-person support.

North Carolina experts discussed CLL, breast cancer, and myeloma treatments and how to expand access to complex cancer care beyond academic centers.

Even top academic centers struggle to keep pace with precision medicine, says William K. Oh, MD, who is prioritizing clinician education at Yale.

Biomarker testing, referrals, screening, treatment access, and clinical trial barriers were examined during this recent IVBM.

In part 2, Christine Pfaff, RPh, MBA, explores reimbursement gaps, new payment models, and payer partnerships needed to expand cellular therapy access.

Oncologists say advances in testing and treatment are outpacing staffing, pay, and access.

In part 2, Rosa Novo discusses how employers can expand access to cancer screening and why they need a greater voice in shaping cancer care.

AI could ease oncology's drug development "traffic jam," while biomarker subsetting drives more personalized cancer care, David Spigel, MD, says.

Amanda Green, MPH, discusses how employers can improve benefit awareness, care navigation, cancer prevention, and cost strategies.

CDC's David A. Siegel, MD, MPH, on rising cancer diagnoses, falling deaths, and where CDC's cancer control resources go next.

Advanced primary care, return-to-work support, and survivorship follow-up are key employer cancer strategies, said Karen van Caulil, PhD.

CDC's Jane Henley, MSPH, explains what's behind falling lung cancer deaths and why 4 in 5 eligible adults still aren't getting screened.

Community oncologists cited prior authorization as a care barrier, even as AI adoption doubled in 2026, according to the Oncology Care Index.

Community oncology faces high costs and staffing hurdles for trials; Lucio N. Gordan, MD, urges pragmatic designs matching real-world patients.

In part 2, David Johnson, MD, MPH, discusses how real-time data can sustain gold carding, ease prior authorization burden, and ensure accountability.

Payers say NCCN guideline concordance sets a baseline for cancer coverage, but cost and formulary variation may still limit access.

Liquid biopsy and at-home phlebotomy are closing precision medicine access gaps nationwide, though tissue remains the gold standard.

The FDA has approved belzutifan plus lenvatinib for advanced ccRCC after PD-1/PD-L1 therapy, expanding treatments for those with disease progression.